HPV testing: IQWiG still sees indications of a benefit in primary screening

June 11, 2014

The Institute for Quality and Efficiency in Health Care (IQWiG) assessed current study results on the benefit of a test for human papillomavirus (HPV) and examined whether its first assessment from January 2012 is still valid. The rapid report published by the Institute on 11 June 2014 answers this question with "yes". IQWiG still sees indications that precursors of cervical cancer can be detected and treated earlier and consequently tumours occur less often in women who underwent this testing.

HPV testing is not reimbursed by SHI funds

In screening for , the German statutory health insurance (SHI) funds currently offer an annual cytologic examination of mucosal cells from a smear taken from the neck of the womb (cervix). This test is called a Pap smear. Since it became known that infection with HPV is the main risk factor for developing cervical cancer, experts have been discussing whether HPV testing is also a suitable screening method or is even superior to a cytologic . The SHI funds currently only reimburse HPV testing in exceptional cases, for example, in cases where the result of a Pap smear is unclear.

New analysis of large study

IQWiG conducted a new search for studies comparing primary screening strategies for cervical cancer based on different screening tests: a strategy including HPV testing alone or in combination with cytology-based testing and a strategy including cytology-based testing alone.

In this update search, they identified no studies that had not already been included in the first assessment. However, they were now able to include the final analysis of one of the largest studies (POBASCAM), for which only an interim analysis had been available in 2011.

Fewer cancer diagnoses in the second screening round

Also under inclusion of the new data, the number of diagnoses for in the second screening round was lower in the HPV group than in the group of women who had only been examined with a cytology-based screening strategy (e.g. Pap smear) in the first screening round. This also applies to the so-called "composite outcome", which not only comprised tumours, but also advanced precursors of cancer. IQWiG therefore determined an indication of a benefit in each case.

There are still no data or no evaluable data available on mortality, quality of life and potential harm.

As the screening strategies applied in the studies varied greatly and could therefore not be compared with each other, the results still do not allow a recommendation for a specific strategy in the German system.

Process of report production

The Federal Joint Committee (G-BA) commissioned IQWiG to prepare the report in an accelerated process, known as a "rapid report". Unlike the normal procedure, no preliminary reports are published in this case. Although a draft version of the report is reviewed by external experts, no hearing at which all interested parties can comment takes place.

IQWiG sent the first benefit assessment to the commissioning agency in November 2011 and published it in January 2012. In October, the G-BA commissioned IQWiG to update its report using the same methodological approach. The present was sent to the G-BA in mid-May 2014.

Explore further: HPV testing: Indications of a benefit in primary screening

Related Stories

HPV testing: Indications of a benefit in primary screening

January 24, 2012
Studies currently available provide indications and a "hint" that precursors of cervical cancer can be detected and treated earlier, and consequently tumours occur less often, in women who underwent testing for human papillomavirus ...

What's the best test for cervical cancer? Pap, HPV or both?

June 9, 2014
Should U.S. women be screened for cervical cancer with Pap tests, HPV tests or both? According to researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) while the merits of screening ...

Longer screening intervals possible with HPV-based tests

January 21, 2014
A new study from Karolinska Institutet in Sweden finds that testing for human papilloma virus (HPV) allows for longer time between screening tests when compared to cytology-based testing. The study is published in the scientific ...

Cervical cancer trial underway in Victoria

May 1, 2014
As the government considers recommendations for changes to cervical cancer screening, UNSW is already a leading partner in a major trial of the new technology in Victoria.

HPV testing could cut cervical cancers by a third

June 14, 2013
(Medical Xpress)—Testing women for the human papillomavirus (HPV) first, instead of using the traditional cervical screening test to detect abnormal cells in the cervix, could prevent around 600 cases of cervical cancer ...

Female doctors twice as likely to screen low-risk women for cervical cancer with HPV test

November 7, 2013
For low-risk women, the likelihood that they get tested for the infection that causes cervical cancer (human papillomavirus or HPV) may depend on what clinic they visit, their doctor's status and whether their provider is ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.